Axsome Therapeutics, Inc. (AXSM) Insider Trading Activity

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Show less

Over the last 12 months, insiders at Axsome Therapeutics, Inc. have bought $200,466 and sold $113.56M worth of Axsome Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Axsome Therapeutics, Inc. have bought $287,335 and sold $41.81M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Coleman Mark (director) — $200,466.

The last purchase of 1,575 shares for transaction amount of $200,466 was made by Coleman Mark (director) on 2025‑09‑08.